Questcor Pharmaceuticals (QCOR) announced after the bell Wednesday that it was informed by the FDA that it will require additional time, beyond the current action date of September 11, 2010, to complete its review of Questcor's supplemental new drug application for H.P. Acthar Gel, in the treatment of infantile spasms. The stock is now down 0.55 on 103K shares.
Questcor Pharmaceuticals posted modest gains early Wednesday and advanced further around midday. Shares finished up by 0.76 at $10.38 on above average volume. The stock rose to over a one-week high and re-crossed its 50-day moving average.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org